Novel Approaches to Diagnosing and Treating Generalized Pustular Psoriasis - Episode 9

Overview of Spesolimab for Management of GPP

Published on: March 29, 2025

Aaron Farberg, MD, FAAD , Harrison Nguyen, MD, MBA, MPH, FAAD , Boni Elewski, MD, FAAD , Johann Gudjonsson, MD, PhD, FAAD

Panelists provide an overview of spesolimab, an IL-36R inhibitor now FDA-approved for treating GPP, discussing the efficacy and safety data from the EFFISAYIL-1 trial (intravenous [IV] formulation) and the EFFISAYIL-2 trial (subcutaneous [SQ] formulation).

Video content above is prompted by the following:

EP. 1: Clinical Presentation and Burden of Disease of Generalized Pustular Psoriasis

EP. 2: Impact of GPP Triggers and Flares on a Patient’s Physical and Mental Health

EP. 3: Approaches to Diagnosing GPP and Distinguishing It From Other Psoriatic Conditions

EP. 4: Challenges for Making a Timely GPP Diagnosis

EP. 5: GPP Pathogenesis and Treatment Goals

EP. 6: Older Treatment Approaches to GPP Management

EP. 7: Addressing the Psychosocial Aspects of GPP Management and the Role of Multidisciplinary Care

EP. 8: Role of IL-36 in GPP Pathogenesis and Treatment

Now Viewing

EP. 9: Overview of Spesolimab for Management of GPP

EP. 10: Utilizing Intravenous and Subcutaneous Formulations of Spesolimab

EP. 11: Future Directions for GPP Management and Key Takeaways

Spesolimab, an IL-36R inhibitor, is now FDA-approved to treat GPP. Can you give a brief overview of spesolimab and the efficacy and safety evidence we have seen to date.
a. EFFISAYIL-1—IV formulation (Bachelez, 2021)
b. EFFISAYIL-2—SQ formulation (Morita, 2023)